Suppr超能文献

肝细胞癌

Hepatocellular carcinoma.

作者信息

Marrero Jorge A

机构信息

Department of Internal Medicine, Division of Gastroenterology, University of Michigan Medical Center, Ann Arbor, 48109, USA.

出版信息

Curr Opin Gastroenterol. 2005 May;21(3):308-12. doi: 10.1097/01.mog.0000159817.55661.ca.

Abstract

PURPOSE OF REVIEW

The incidence of hepatocellular carcinoma (HCC) is expected to continue to increase over the next two decades. The risk factors for the development of HCC are unknown and there is a lack of standardization of the diagnostic criteria for HCC. Our aim is to review the latest information regarding the risk factors, surveillance and diagnosis of this tumor.

RECENT FINDINGS

Alcohol, tobacco, obesity, diabetes and viral etiology interact together to increase the risk of hepatocellular carcinoma in patients with cirrhosis, which may allow us to identify a high-risk group for HCC among patients with cirrhosis. Several studies showed that surveillance of cirrhotic patients is cost-effective and leads to an overall improvement in survival. This year a study from the United Network of Organ Sharing in the United States indicated that 30% of patients were understaged by imaging pre-transplant and 31% of patients with a diagnosis of stage 1 HCC (single lesion < 2 cm in diameter) did not have a tumor on the explant examination. Another study showed that washout of arterially enhancing lesions is very sensitive and specific for a diagnosis of HCC.

SUMMARY

Not all patients with cirrhosis have an equal risk for developing hepatocellular carcinoma. Therefore, further studies should stratify the risk of HCC so surveillance is tailored to those at the highest risk. Standardization of the diagnostic criteria of HCC is critically important for better patient care and future research. Washout of arterially enhancing lesions should be important criteria of HCC.

摘要

综述目的

预计在未来二十年中,肝细胞癌(HCC)的发病率将持续上升。HCC发生的危险因素尚不清楚,且HCC的诊断标准缺乏标准化。我们的目的是综述有关该肿瘤危险因素、监测及诊断的最新信息。

最新发现

酒精、烟草、肥胖、糖尿病和病毒病因相互作用,增加了肝硬化患者发生肝细胞癌的风险,这可能有助于我们在肝硬化患者中识别出HCC的高危人群。多项研究表明,对肝硬化患者进行监测具有成本效益,并能全面提高生存率。今年美国器官共享联合网络的一项研究表明,30%的患者在移植前的影像学检查中分期过低,31%诊断为1期HCC(单个病灶直径<2 cm)的患者在移植肝检查中未发现肿瘤。另一项研究表明,动脉强化病灶的廓清对HCC的诊断非常敏感且特异。

总结

并非所有肝硬化患者发生肝细胞癌的风险都相同。因此,进一步的研究应分层HCC风险,以便针对最高风险人群进行监测。HCC诊断标准的标准化对于改善患者护理和未来研究至关重要。动脉强化病灶的廓清应成为HCC的重要诊断标准。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验